Zimmer Biomet Holdings ( (ZBH) ) has released its Q1 earnings. Here is a breakdown of the information Zimmer Biomet Holdings presented to its investors.
Zimmer Biomet Holdings, Inc., a global leader in medical technology, specializes in orthopedic products and solutions designed to enhance mobility and health. The company operates in over 25 countries and is known for its innovative approach, integrating digital and robotic technologies.
In its first-quarter 2025 financial results, Zimmer Biomet reported net sales of $1.909 billion, reflecting a 1.1% increase from the previous year, or 2.3% on a constant currency basis. The company achieved a diluted earnings per share of $0.91, with an adjusted figure of $1.81, and highlighted its strategic acquisition of Paragon 28.
Key financial metrics for the quarter included a net earnings increase to $182 million, with adjusted net earnings reaching $361.1 million. The acquisition of Paragon 28 is expected to bolster Zimmer Biomet’s position in the high-growth foot and ankle segment. The company also showcased new innovations at the AAOS annual meeting and received FDA clearance for a new knee implant component.
Looking forward, Zimmer Biomet has updated its full-year 2025 revenue guidance to account for the Paragon 28 acquisition and currency impacts, projecting a reported revenue change of 5.7% to 8.2%. The company remains focused on innovation and growth, with plans to leverage its expanded portfolio and strategic initiatives.
Zimmer Biomet’s management remains optimistic about the company’s future, emphasizing continued innovation and strategic expansion to drive growth in the orthopedic sector. The integration of Paragon 28 and new product launches are expected to contribute positively to the company’s performance in the coming quarters.